Octagon Capital Advisors LP / TCE2
Octagon Capital Advisors LP’s Celldex Therapeutics Inc New Position
Does Octagon Capital Advisors LP own Celldex Therapeutics Inc New (TCE2)? Not currently — the last reported position was 707.5K shares worth $28M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$28M
Q4 2023
Shares
707.5K
% of Portfolio
+4.49%
Quarters Held
13
position exited
Position History TCE2
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2023 | 707.5K | $28M | +4.49% |
| Q3 2023 | 759.9K | $21M | +3.21% |
| Q2 2023 | 759.9K | $26M | +3.59% |
| Q1 2023 | 759.9K | $27M | +3.93% |
| Q4 2022 | 761.4K | $34M | +5.28% |
| Q3 2022 | 761.4K | $21M | +3.69% |
| Q2 2022 | 761.4K | $21M | +5.48% |
| Q1 2022 | 761.4K | $26M | +5.61% |
| Q4 2021 | 761.4K | $29M | +5.73% |
| Q3 2021 | 761.4K | $41M | +10.12% |
| Q2 2021 | 561.4K | $19M | +3.89% |
| Q1 2021 | 561.4K | $12M | +4.36% |
| Q4 2020 | 1.04M | $18M | +6.32% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of TCE2.